Literature DB >> 28795981

Summary of the British Transplantation Society UK Guidelines for Hepatitis E and Solid Organ Transplantation.

Stuart McPherson1, Ahmed M Elsharkawy2, Michael Ankcorn3, Samreen Ijaz4, James Powell5, Ian Rowe6, Richard Tedder7, Peter A Andrews8.   

Abstract

The incidence and prevalence of hepatitis E virus (HEV) infection has increased in many developed countries over the last decade, predominantly due to infection with genotype 3 (G3) HEV. Infection with HEV G3 is important in transplant recipients because it can persist in immunosuppressed individuals, leading, if untreated, to the development of chronic hepatitis and significant liver fibrosis. The British Transplantation Society (BTS) has developed Guidelines for "Hepatitis E and Solid Organ Transplantation" to inform clinical teams and patients about hepatitis E, to help increase the recognition of persistent hepatitis E infection, and to provide clear guidance on its management. This guideline was published on the BTS website in June 2017 and aims to review the evidence relating to the diagnosis and management of persistent hepatitis E in solid organ transplant recipients and the methods of prevention of HEV infection. In line with previous guidelines published by the BTS, the guideline has used the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) system to rate the strength of evidence and recommendations. This article includes a summary overview of hepatitis E and transplantation with key references, and the statements of recommendation contained within the guideline. It is recommended that the full guideline document is consulted for complete details of the relevant references and evidence base. This may be accessed at https://bts.org.uk/guidelines-standards/.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28795981     DOI: 10.1097/TP.0000000000001908

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  15 in total

1.  Identification of the interferon-inducible GTPase GBP1 as major restriction factor for the Hepatitis E virus.

Authors:  Mirco Glitscher; Kiyoshi Himmelsbach; Kathrin Woytinek; Anja Schollmeier; Reimar Johne; Gerrit J K Praefcke; Eberhard Hildt
Journal:  J Virol       Date:  2021-01-20       Impact factor: 5.103

Review 2.  Hepatitis E Virus in the Food of Animal Origin: A Review.

Authors:  Gianluigi Ferri; Alberto Vergara
Journal:  Foodborne Pathog Dis       Date:  2021-03-30       Impact factor: 3.171

3.  Chronic genotype 1 hepatitis E infection from immunosuppression for ileo-colonic Crohn's disease.

Authors:  Anne E M Robins; David J Bowden; William T H Gelson
Journal:  Oxf Med Case Reports       Date:  2018-08-25

4.  Hepatitis E Infection in HIV-Infected Patients.

Authors:  Antonio Rivero-Juarez; Pedro Lopez-Lopez; Mario Frias; Antonio Rivero
Journal:  Front Microbiol       Date:  2019-06-26       Impact factor: 5.640

5.  Clinical presentations of Hepatitis E: A clinical review with representative case histories.

Authors:  Abhishek Chauhan; Gwilym Webb; James Ferguson
Journal:  Clin Res Hepatol Gastroenterol       Date:  2019-02-23       Impact factor: 2.947

6.  Convalescent plasma therapy for persistent hepatitis E virus infection.

Authors:  Michael Ankcorn; Jennifer Gallacher; Samreen Ijaz; Yusri Taha; Heli Harvala; Sheila Maclennan; Emma C Thomson; Chris Davis; Joshua B Singer; Ana da Silva Filipe; Katherine Smollett; Marc Niebel; Malcolm G Semple; Richard S Tedder; Stuart McPherson
Journal:  J Hepatol       Date:  2019-05-08       Impact factor: 25.083

7.  A Nationwide Survey of Hepatitis E Virus Infection and Chronic Hepatitis in Heart and Kidney Transplant Recipients in Japan.

Authors:  Yohei Owada; Yukio Oshiro; Yuki Inagaki; Hiroshi Harada; Nobuhiro Fujiyama; Naoki Kawagishi; Takashi Yagisawa; Joichi Usui; Naotake Akutsu; Yoshihiro Itabashi; Kazuhide Saito; Yoshihiko Watarai; Naotsugu Ichimaru; Ryoichi Imamura; Miyaji Kyakuno; Kentaro Ide; Yuichi Shibuya; Yasuhiro Okabe; Minoru Ono; Konosuke Sasaki; Akira Shiose; Kazumasa Yamagishi; Hiroshi Ohnishi; Shigeo Nagashima; Masaharu Takahashi; Kenji Yuzawa; Hiroaki Okamoto; Nobuhiro Ohkohchi
Journal:  Transplantation       Date:  2020-02       Impact factor: 5.385

8.  Inhibition of Hepatitis E Virus Spread by the Natural Compound Silvestrol.

Authors:  Mirco Glitscher; Kiyoshi Himmelsbach; Kathrin Woytinek; Reimar Johne; Andreas Reuter; Jelena Spiric; Luisa Schwaben; Arnold Grünweller; Eberhard Hildt
Journal:  Viruses       Date:  2018-06-02       Impact factor: 5.048

9.  Performance of a commercial assay for detecting and quantifying HEV RNA in faeces.

Authors:  Florence Abravanel; Audrey Lacipière; Sébastien Lhomme; Martine Dubois; Luce Minier; Jean-Marie Peron; Laurent Alric; Nassim Kamar; Jacques Izopet
Journal:  J Clin Virol       Date:  2018-10-10       Impact factor: 3.168

10.  Ribavirin as a First Treatment Approach for Hepatitis E Virus Infection in Transplant Recipient Patients.

Authors:  Antonio Rivero-Juarez; Nicolau Vallejo; Pedro Lopez-Lopez; Ana Isabel Díaz-Mareque; Mario Frias; Aldara Vallejo; Javier Caballero-Gómez; María Rodríguez-Velasco; Esther Molina; Antonio Aguilera
Journal:  Microorganisms       Date:  2019-12-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.